In this CE activity, using a visually engaging format, participants will review the pathophysiology of AA, explore the mechanisms of action of JAK inhibitors, and evaluate current and emerging clinical data supporting their use in adolescents and adults with severe disease.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Address:
- 6900 Grove Road
Pricing
100% of listed courses are free
256 of 256 courses listed here are free.
Collected from the provider’s public pages · source
Specialties served/covered
- Adolescent Medicine
- Allergy & Clinical Immunology
- Cardiovascular Disease
- Communication & Shared Decision-Making
- Dermatology
- Diagnostic Radiology
- Endocrinology, Diabetes & Metabolism
- Family Medicine
- Gastroenterology
- General Internal Medicine
- General Operative Anesthesia
- General Otolaryngology
- General Pediatrics
- Infectious Disease
- Medical Oncology
- Metabolic & Bariatric Surgery
- Mood & Anxiety Disorders
- Nephrology
- Neurology
- Ophthalmology
- Pediatric Gastroenterology
- Pediatric Infectious Diseases
- Practice Management & Ethics
- Psychopharmacology
- Psychotic Disorders
- Pulmonary Disease
- Rheumatology
- Rhinology
- Anesthesiology
- Cardio-Vascular
- Cross-Specialty
- ENT & Head Neck
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Oncology & Hematology
- Pediatrics
- Primary care
- Psychiatry
- Radiology
- Surgery
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Enduring / On-demand
- Credit · Up to 0.5 credits
- Commercial Support
-
ReleasedJul 15, 2026
-
Last day to claim creditJul 15, 2027 9 months left
-
Smart Patients +1 Improving Patient Satisfaction in Alopecia Areata: Rationale and Safety Considerations for JAK Inhibitors
-
Medscape, LLC Keeping Pace With Advances in Alopecia Areata
-
Answers in CME Inc. (AiCME) Looking Ahead in Atopic Dermatitis: OX40/OX40L Mechanisms, Multidisciplinary Care, and Meaningful Patient Outcomes
-
Vindico Medical Education, LLC TL1A Inhibition for IBD: Emerging Therapies at the Intersection of Inflammation and Fibrosis
-
Vindico Medical Education, LLC IBD Advancements: The Promise of TL1A-Targeted Therapies
-
National Lipid Association +1 CETP Inhibition: Exploring the Cardiovascular and Neurocognitive Implications
